gastrointestinal inflammatory diseases

Linaprazan glurate inhibits both exogenously and endogenously stimulated gastric acid secretion and can be utilized in studies on gastrointestinal inflammatory diseases and peptic ulcer diseases.

Substance P Receptor Antagonist 1 has potential applications in treating gastrointestinal disorders, inflammatory diseases, respiratory conditions, and central nervous system disorders.

Fulvic Acid is a natural product of humus produced by microorganisms in soil, sediment or aquatic environments. Fulvic acid is a phenolic acid and fungal metabolite isolated from Penicillium for the first time. Fulvic Acid inhibits the dimerization of amyloid b (17-42) (AB17-42), destroys the pre-formed trimer of AB17-42, and binds to the catalytic site of phosphodiesterase 5A (PDE5A), which can regulate the body's immune system, affect the oxidation state of cells, and improve gastrointestinal function. Fulvic Acid can be used as an oxidant or reducing agent and has the potential to study chronic inflammatory diseases such as diabetes.

Zastaprazan (JP-1366, compound 6) is a potassium-competitive acid blocker and proton pump inhibitor that suppresses gastric acid secretion, indicated for gastro-oesophageal reflux disease (GERD).

LON63114, also known as FFA2-Agonist-1 is a selective orthosteric agonist of human FFA2. FFA2-Agonist-1 is potentially useful in the treatment of gastrointestinal disorders and inflammatory bowel diseases. LON63114 was reported in WO2011076732. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

Catechin 7-O-β-D-glucopyranoside is a major bioactive constituent associated with antioxidant and anti-inflammatory benefits of PHCR seed extracts and has been recognized as a promising research agent for intestinal inflammatory disorders. Catechin 7-O-β-D-glucopyranoside demonstrates strong biological effects supporting future pharmaceutical development of CGP-containing formulations against gastrointestinal inflammatory diseases.

Anti-MMP9 Antibody is a highly specific neutralizing antibody against Matrix Metalloproteinase-9 (MMP9). By inhibiting the enzymatic activity of MMP9, it effectively prevents extracellular matrix degradation, thereby suppressing tumor invasion, metastasis, and angiogenesis, and has research value in gastrointestinal tumors and inflammatory diseases such as Crohn's disease.

Kobusin, a bisepoxylignan compound isolated from Pnonobio biondii Pamp, demonstrates CFTR and CaCC chloride channel activation properties while exhibiting inhibitory effects on ANO1/CaCC channels.

BigGastrinI, human (TFA), is a gastrointestinal hormone comprised of 34 amino acids. It can serve as a potential substance in the study of conditions such as cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurological disorders, or cardiovascular diseases.